Thomas Malefyt
Plus aucun poste en cours
Profil
Thomas Malefyt worked as Vice President-Technical Operations at Synosia Therapeutics AG and Synosia Therapeutics, Inc. He also worked as a Principal at Smithkline & French Laboratories US, Inc. Malefyt holds a doctorate degree from the University of California, Berkeley.
Anciens postes connus de Thomas Malefyt
| Sociétés | Poste | Fin |
|---|---|---|
| Smithkline & French Laboratories US, Inc. | Corporate Officer/Principal | - |
Synosia Therapeutics, Inc.
 Synosia Therapeutics, Inc. Medical SpecialtiesHealth Technology Synosia Therapeutics, Inc. used to develop products for unmet medical needs in psychiatry and neurology. The company was founded in December 2005 and was headquartered in San Francisco, CA. | Directeur Technique/Scientifique/R&D | - |
Synosia Therapeutics AG
 Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds. | Directeur Technique/Scientifique/R&D | - |
Formation de Thomas Malefyt
| University of California, Berkeley | Doctorate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Synosia Therapeutics AG
Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds. | Health Technology |
| Smithkline & French Laboratories US, Inc. | |
Synosia Therapeutics, Inc.
Synosia Therapeutics, Inc. Medical SpecialtiesHealth Technology Synosia Therapeutics, Inc. used to develop products for unmet medical needs in psychiatry and neurology. The company was founded in December 2005 and was headquartered in San Francisco, CA. | Health Technology |
